Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Conditions: Ovarian Cancer Interventions: Drug: Pembrolizumab; Drug: Bevacizumab; Drug: Cyclophosphamide Sponsors: M.D. Anderson Cancer Center Not yet recruiting

https://clinicaltrials.gov/study/NCT06083844

Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials